Navigation Links
Abviva Engages W.T. Uniack & Co. As Independent Auditor
Date:6/4/2010

SANTA BARBARA, Calif., June 4 /PRNewswire-FirstCall/ -- Abviva, Inc. (Pink Sheets: ABVV), a biomedical company engaged in the development and commercialization of breast cancer related applications of Mammastatin, today provided further details about worldwide patent protection for its breast cancer risk assessment technology.  

Abviva appoints W.T. Uniack & Co. as its independent auditor.  Abviva is working hard to regain compliance and this is the next step.  Uniack will perform the audit for the fiscal years 2008 and 2009.  Abviva is moving as quickly as possible to complete these audits.

"We look forward to building shareholder value by completing these audits and becoming fully OTCBB compliant.  This is the first of many announcements that will demonstrate the Company's dedication to increasing the Company's bottom line as well as shareholder value," said Barrett Evans, CEO of Abviva, Inc.

About Abviva

Abviva, Inc. is a biomedical company engaged in the innovation, development and commercialization of breast cancer related applications of Mammastatin, a growth inhibitory protein discovered at the University of Michigan Cancer Center that demonstrated anti-breast cancer properties. The discovery was developed into a simple breast cancer diagnostic blood test that demonstrated healthy women have high or normal levels of the protein and women with breast cancer have no detectable or very low levels of the protein. Abviva intends to commercialize the Mammastatin Serum Assay as a reference test through its wholly owned subsidiary laboratory under CLIA certification.  

Statements in this press release that are not strictly historical facts are "forward-looking" statements (identified by the words "believe", "estimate", "project", "expect" or similar expressions) within the meaning of the Private Securities Litigation Reform Act of 1995. These statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, continued acceptance of the Company's products and services in the marketplace, competitive factors, changes in the regulatory environment, and other risks detailed in the Company's periodic report filings with the Securities and Exchange Commission. The statements in this press release are made as of today, based upon information currently known to management, and the Company does not undertake any obligation to publicly update or revise any forward-looking statements.


'/>"/>
SOURCE Abviva, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
2. Vion Pharmaceuticals Engages Merriman Curhan Ford to Evaluate Strategic Alternatives
3. Secure eHealth, LLC Engages as a Consultant GSI Health Whose Principal and CEO is the Former Senior Advisor to National Coordinator for Health Information Technology
4. Vystar Corporation Engages The Investor Relations Group
5. Speedus Engages Morgan Joseph to Evaluate Strategic Alternatives for Zargis Subsidiary
6. Wound Management Technologies, Inc. Engages Miller Tabak, A National Investment Banking Firm Specializing in the Healthcare Market Space
7. GeoVax Labs Engages The Investor Relations Group
8. Frost & Sullivan: Western European Markets Confirm Undisputed Convenience and Cost Benefit of Custom Procedure Trays
9. Boston Scientific and Johnson & Johnson Announce Settlement of Patent Disputes
10. Tata Interactive Systems Partners With Bersin & Associates for Exclusive Executive Learning Forum - TLF 2009
11. Sigma-Aldrich (Nasdaq: SIAL) Announces Appointment of George Miller as Sr. Vice President, General Counsel & Secretary
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/18/2017)... and Markets has announced the addition of the "Contraceptives - Global ... ... US, Canada , Japan , ... America , and Rest of World. Annual estimates and forecasts are ... is provided for these markets. Market data and analytics are derived from ...
(Date:2/17/2017)... Feb. 17, 2017  Ethicon, Inc. today announced ... a privately held medical device company that manufactures ... System, a novel minimally invasive device for the ... Medical will enable Ethicon to offer patients a ... Nissen fundoplication surgical procedure. 1 ...
(Date:2/17/2017)... Theravance Biopharma, Inc. (NASDAQ: ... announced the presentation of positive clinical data for ... kinase (JAK) inhibitor designed to be intestinally restricted, ... European Crohn,s and Colitis Organization (ECCO). In a ... its completed Phase 1 study of single-ascending and ...
Breaking Medicine Technology:
(Date:2/17/2017)... CA (PRWEB) , ... February 17, 2017 , ... ... that their Chief Executive Officer, George Rogers, was named to Staffing Industry Analysts' ... The Staffing 100 honors those who have made notable contributions to the staffing ...
(Date:2/17/2017)... ... , ... Like most hospitals across the nation, Onslow Memorial Hospital is looking ... Readmission Reduction Program (HRRP), the return of a patient to the hospital within 30 ... While many providers are struggling to leverage limited resources and technology, Onslow Memorial Hospital ...
(Date:2/17/2017)... ... February 17, 2017 , ... The Mason ... to families and business owners in and around the Hampton Roads metropolitan region, ... prevent all forms of domestic violence. , There are multiple categories of domestic ...
(Date:2/16/2017)... ... February 17, 2017 , ... Harsha Chigurupati knows ... of research, development and clinical trials, the founder of Chigurupati Technologies has invented ... of FDA approved ingredients that when infused into alcohol, protect the consumer’s liver ...
(Date:2/16/2017)... ... 17, 2017 , ... Teaching nursing care of vulnerable children is the focus ... is being created with the support of the Hearst Foundations. An initiative of the ... address what has been identified as a critical gap in preparing the next generation ...
Breaking Medicine News(10 mins):